Six times in a month and a half! Andon Health Co.Ltd(002432) the market value of “refined” and “traditional Chinese medicine Mao” has evaporated by nearly 30 billion because

count down! In two more trading days, the A-share trading in 2021 will be closed soon. On December 29, the annual turnover of Shanghai and Shenzhen stock markets reached 255.1 trillion yuan, which has exceeded 254.6 trillion yuan in 2015, a record high and attracted much attention.

On December 29, the three major A-share indexes made a collective correction. As of the closing, the Shanghai Composite Index fell 0.91% to 3597.00 points and fell 3600 points; The Shenzhen Component Index fell 1.24% to 14653.82 points; The gem index fell 1.40% to 3281.90. The total turnover of Shanghai and Shenzhen stock markets reached 990.7 billion yuan; The net purchase of funds from northbound was 662 million yuan, which was a net purchase for three consecutive days; Among them, the net purchase of Shanghai Stock connect was 186 million yuan and that of Shenzhen Stock connect was 476 million yuan. Overall, stocks in the two cities rose less and fell more.

Specifically, on Wednesday, the civil aviation sector showed a strong performance, with the sector rising by 2.96%, and China Express Airlines Co.Ltd(002928) , Juneyao Airlines Co.Ltd(603885) rising by more than 5%.

In addition, the salt lake lithium extraction and lithium ore plates continued to be strong, Tibet Summit Resources Co.Ltd(600338) two connected plates. Citic Securities Company Limited(600030) said that the current lithium price is at a high level, the market’s awareness of price rise is gradually passivated, and the continued rise of price may have a reverse effect on the stock market. In the fourth quarter of 2021, the price of lithium carbonate in China increased significantly compared with the first three quarters, and the performance growth peak of relevant enterprises is expected to appear in the fourth quarter, driving the enterprise valuation back to a lower level. It is expected that the lithium price will remain high in 2022, and the price inflection point will not appear in the short term. It is expected that the lithium salt price center in 2022 will be significantly higher than that in 2021, which will drive the company’s performance in the lithium sector to increase significantly. The valuation advantage and allocation value of the lithium sector in 2022 are high.

The consumer wine and beverage sector, which had an eye-catching performance, led the decline in the two cities today. Among them, Kweichow Moutai Co.Ltd(600519) , Wuliangye Yibin Co.Ltd(000858) fell by more than 4%, and Luzhou Laojiao Co.Ltd(000568) , Anhui Gujing Distillery Company Limited(000596) fell by more than 6%.

It is noteworthy that, in terms of individual stocks, there is obvious differentiation in pharmaceutical stocks. Chinese medicine plate is also clearly differentiated. Daily limit of Jinghua Pharmaceutical Group Co.Ltd(002349) , Chongqing Pharscin Pharmaceutical Co.Ltd(002907) , Guangdong Zhongsheng Pharmaceutical Co.Ltd(002317) , Wanbangde Pharmaceutical Holding Group Co.Ltd(002082) ; Dali Pharmaceutical Co.Ltd(603963) , Henan Lingrui Pharmaceutical Co.Ltd(600285) , Guangyuyuan Chinese Herbal Medicine Co.Ltd(600771) , Beijing Tongrentang Co.Ltd(600085) fell more than 5%.

Andon Health Co.Ltd(002432) “full of evil spirit” 13 days and 10 boards. Since November 15, it has increased by 636%.

In terms of news, on December 28, the “14th five year plan” for the development of medical equipment industry was released. The plan proposed that by 2025, the level of advanced foundation and industrial chain modernization of medical equipment industry will be significantly improved, the effective supply of mainstream medical equipment will be basically realized, and the performance and quality of high-end medical equipment products will be significantly improved, Initially form a comprehensive support capacity for public health and medical health needs. By 2035, the R & D, manufacturing and application of medical equipment will be upgraded to the world advanced level. China is in the forefront of a country with innovative medical equipment, providing strong support for ensuring people’s all-round and life-cycle health services.

On Wednesday, “Chinese herbal medicine Mao” Zhangzhou Pientzehuang Pharmaceutical Co.Ltd(600436) fell by the limit after rapid diving after opening. As of the closing, the share price was reported to 428.54 yuan, with a market value of 258.5 billion yuan. The market value evaporated 28.7 billion yuan today. Market analysts said that excluding the upward factors of raw material prices, the fund adjusted its positions at the end of the year and transferred out some varieties with high prices and valuations, or one of the reasons for the sharp decline of Zhangzhou Pientzehuang Pharmaceutical Co.Ltd(600436) .

Zhangzhou Pientzehuang Pharmaceutical Co.Ltd(600436) today, the volume limit fell. According to the Dragon Tiger list, the Shanghai Stock connect sold 451 million yuan and bought 486 million yuan. The three institutions sold 504 million yuan and the two institutions bought 102 million yuan.

According to the data, the main products of Zhangzhou Pientzehuang Pharmaceutical Co.Ltd(600436) company cover many fields such as liver disease medication, cold medication and dermatology medication. The core products are Zhangzhou Pientzehuang Pharmaceutical Co.Ltd(600436) series products, including Zhangzhou Pientzehuang Pharmaceutical Co.Ltd(600436) , Zhangzhou Pientzehuang Pharmaceutical Co.Ltd(600436) capsules, compound Zhangzhou Pientzehuang Pharmaceutical Co.Ltd(600436) buccal tablets, compound Zhangzhou Pientzehuang Pharmaceutical Co.Ltd(600436) ointment, compound Zhangzhou Pientzehuang Pharmaceutical Co.Ltd(600436) hemorrhoids ointment, etc. In addition, in recent years, the company has actively arranged classic prescriptions, produced and sold traditional Chinese medicine products such as “Angong Niuhuang Pill” to enrich the company’s product pipeline. The company’s holding subsidiary pharmaceutical logistics company is based on modern pharmaceutical logistics and strives to expand and extend the upstream and downstream of the pharmaceutical distribution industrial chain of “distribution, maintenance and promotion”.

on Wednesday (December 29) prepared by: Zhang Ying

For the recent shock consolidation of the market, where is the future of a shares? Major institutions hold different views.

Guosheng Securities: near the end of the year, the current market has a clear mood of avoiding high and low, and the plates with large increase in the early stage have ushered in adjustment. The main reasons are the large uncertainty of market liquidity at the end of the year and the lack of capacity due to the fact that the northbound funds are only traded for one trading day this week. In terms of operation, we should pay more attention to the direction of high performance growth in the coming year in the future. At present, the adjustment range of this round of boom track is greater than 15%. As the direction of sustained boom in the coming year, we can pay more attention gradually; In addition, the overall A profit growth rate decreased in 2022 or larger. Baijiu and the selected food sector with stable growth can also be concerned.

Wanlian Securities: it is expected that the overall A-share market will remain volatile next year, and the structural highlights deserve attention. Next year, the overall liquidity environment will be better, and incremental funds will continue to enter the market. Under the background of the unchanged tone of “housing, housing and non speculation”, the net value transformation of bank financial management and the rising risk of overseas stock market, the attraction of A-Shares has increased, and individual investors, financial institutions and foreign capital will continue to allocate a shares. In terms of industry configuration, three main lines are recommended: first, silicon leader, cell module and photovoltaic integration leader in photovoltaic, leading complete machine manufacturer in wind power, fuel cell in hydrogen energy, hydrogen production from industrial by-products and upstream lithium ore, artificial graphite, membrane electrolyte and other carbon neutralization main lines in the industrial chain of new energy vehicles; Second, the main line of breeding benefiting from the transmission of inflation and the recovery of pork prices; Third, there are structural opportunities for the supply side shortage situation to improve, the semiconductor that is expected to be in large quantities next year and the high-end manufacturing sector that maintains a higher outlook and has a clear demand side.

Liu Youhua, director of private placement network research, Mr : today, the market is weak in the market, and the heavyweights such as Baijiu and banks are in the top. The stock index is also falling 3600 points again, and the turnover of the two cities has also shrunk to below trillion scale. The specific reason is that the recent rebound of the market is weak and the height is limited. The market can only choose to step back on the low point again and continue to build the bottom. Next, the index may step back on last week’s low again, but there is little space below. After continuous adjustment, the market risk is gradually released. It is about to enter 2022, and the long-awaited spring market may also be staged. However, it is necessary to be vigilant against the collapse of individual stocks with huge growth this year and the possible style switching of the market. We can focus on high-quality stocks with sufficient adjustment time and space.

Liu Huiming, manager of Honghan Investment Fund: looking forward to 2022, China’s macro economy is facing certain pressure, and the overseas market is also facing many uncertainties. However, the overall liquidity is still relatively loose. Therefore, it is judged that the space up and down the market is limited in the near future. Before there are new hot spots in the market, we should control our positions and avoid chasing up and killing down. In terms of industry configuration, we still maintain our previous view, and military industry, large consumption, intelligent driving and other industries are expected to run through 2022. At present, the market is in a blank window period of policy and news. You can wait for the emergence of new hot plates or clear bottom signals in key promising industries.

Hao Xinming, manager of Fangxin Wealth Investment Fund: today, the consumer sector led by Maotai fell at a high level, and the trend of new energy was also soft. The two mainstream sectors were depressed at the same time, resulting in the decline of the index, and the small and medium-sized stocks led by CSI 1000 were relatively active. The market of switching between consumer medicine, new energy and cyclical stocks has continued for more than half a year, and the trading volume has always been trillion level index, but it can not go out of the trend. The main reason for this situation is that the epidemic factors have caused the expectation of extreme differentiation of policy effects in different industries. The strong are stronger and the weak are weaker. Resources continue to gather in the deterministic field. This change can not form a joint force, so it is difficult to have the whole market trend. Next, the market is still affected by monetary and fiscal policies, epidemic situation and other factors. When the structural differentiation is too intense, there may be a certain return, but it still changes. While the index fluctuates, there are structural opportunities between plates. Under the general pattern of national countercyclical regulation and moderately loose liquidity, there is valuation pressure and policy support, and the shock is still the main melody of the future market.

He Jinlong, general manager of Meili Investment: the current market is dominated by weak shocks, and Shanghai Stock Exchange fluctuates around 3600. The market rhythm mainly focuses on the industrial chain of consumption and real estate, including food and beverage, agriculture, forestry, animal husbandry and fishery and infrastructure industries, while the new energy and cycle sectors with outstanding performance this year have experienced a correction. We believe that the determination of the central economic work conference to stabilize growth, the overall reduction of reserve requirement and LPR, and the signal of capital easing in the medium and short term will not change for the time being. According to the market of China’s counter cyclical policy in previous years, the broad-based index basically rose to a certain extent. Therefore, investors can consider the gradual allocation of industries whose valuation returns to a reasonable range. Due to the valuation differentiation in the short term, the performance of some enterprises in the growth sector will also show a certain degree of differentiation trend. For the future profit-making effect, investors still need to grasp the opportunity of structural market from bottom to top, focus on individual stocks, ignore the index and follow the trend.

(voice of Securities Daily)

 

- Advertisment -